On Tuesday, Protagonist Therapeutics got an upgrade for its IBD SmartSelect Composite Rating from 77 to 96.
The new score tells you the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
Protagonist Therapeutics has now climbed above a proper buy zone after clearing the 48.89 entry in a consolidation.
Discover The 3 Keys To Successful Stock Investing
One weak spot is the company's 61 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 350% rise in earnings for Q4. Top line growth increased 184%, up from -100% in the prior quarter. That marks one quarter of increasing revenue gains.
Protagonist Therapeutics earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
